Pembrolizumab (Keytruda) for metastatic castration‐resistant prostate

Pembrolizumab is a type of immunotherapy. It stimulates the body’s immune system to fight cancer cells. Pembrolizumab targets and blocks a protein called PD ‐L1 on the surface of certain immune cells called T‐cells. Blocking the PD‐L1 protein allows the T‐cells to find and kill the cancer cells. It is administered as a drip into a vein every three weeks for up to 35 cycles. If approved, pembrolizumab will offer an alternative treatment option for patients with metastatic castration‐resistant prostate cancer (mCRPC) in those that have received prior treatment with docetaxel and at least one second-generation anti‐androgen therapy.